Clinical manifestations are complex and often involve multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological evaluations.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnoses and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic disorders have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of carcinogenicity associated with chronic coronary thrombosis. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.